CK2 modulation of NF-κB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules

Clinical Cancer Research

Volumn 16, Issue 8, 2010, Pages 2295-2307

  Brown, Matthew S ^a   Diallo, Oumou T ^a   Hu, Michael ^a   Ehsanian, Reza ^a   Yang, Xinping ^a   Arun, Pattatheyil ^a   Lu, Hai ^a   Korman, Vicci ^b   Unger, Gretchen ^b   Ahmed, Khalil ^c   Van Waes, Carter ^a   Chen, Zhong ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b GeneSegues   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE II; CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; NANOCAPSULE; OLIGODEOXYNUCLEOTIDE; OLIGONUCLEOTIDE; PROTEIN P53; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL SURVIVAL; CONTROLLED STUDY; DNA BINDING; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HEAD AND NECK CANCER; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CASEIN KINASE II; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; HEAD AND NECK NEOPLASMS; HUMANS; LUCIFERASES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOCAPSULES; NF-KAPPA B; OLIGONUCLEOTIDES, ANTISENSE; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; WOUND HEALING;

EID: 77950985649     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3200     Document Type: Article

References (50)

1. Pinna LA. Protein kinase CK2: a challenge to canons. J Cell Sci 2002; 115:3873-3878
2. Guerra B, Issinger OG. Protein kinase CK2 in human diseases. Curr Med Chem 2008;15:1870-1886
3. Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K. Protein kinase CK2 signal in neoplasia. Histol Histopathol 2001;16:573-582 (Pubitemid 32297655)
4. Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 2003;369:1-15.
5. Ahmad KA, Wang G, Unger G, Slaton J, Ahmed K. Protein kinase CK2-a key suppressor of apoptosis. Adv Enzyme Regul 2008;48: 179-187
6. Trembley JH, Wang G, Unger G, Slaton J, Ahmed K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci 2009;66:1858-1867
7. Guerra B, Boldyreff B, Sarno S, Cesaro L, Issinger OG, Pinna LA. CK2: a protein kinase in need of control. Pharmacol Ther 1999;82: 303-313 (Pubitemid 29255926)
8. Ahmed K, Gerber DA, Cochet C. Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol 2002;12:226-230 (Pubitemid 34327615)
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
10. Faust RA, Gapany M, Tristani P, Davis A, Adams GL, Ahmed K. Elevated protein kinase CK2 activity in chromatin of head and neck tumors: association with malignant transformation. Cancer Lett 1996;101:31-35 (Pubitemid 26060189)
11. Gapany M, Faust RA, Tawfic S, Davis A, Adams GL, Ahmed K. Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck. Mol Med 1995;1:659-666
12. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J 2003;17:349-368
13. Van Waes C. Nuclear factor-κB in development, prevention, and therapy of cancer. Clin Cancer Res 2007;13:1076-1082 (Pubitemid 46424045)
14. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell 2008;132:344-362
15. Allen CT, Ricker JL, Chen Z, Van Waes C. Role of activated nuclear factor-κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck 2007;29:959-971
16. Brown M, Cohen J, Arun P, Chen Z, Van Waes C. NF-κB in carcinoma therapy and prevention. Expert Opin Ther Targets 2008;12:1109-1122
17. Yu M, Yeh J, Van Waes C. Protein kinase casein kinase 2 mediates inhibitor-κB kinase and aberrant nuclear factor-κB activation by serum factor(s) in head and neck squamous carcinoma cells. Cancer Res 2006;66:6722-6731 (Pubitemid 44085630)
18. Shen J, Channavajhala P, Seldin DC, Sonenshein GE. Phosphorylation by the protein kinase CK2 promotes calpain-mediated degradation of IκBα. J Immunol 2001;167:4919-4925 (Pubitemid 33009721)
19. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE. Protein kinase CK2 promotes aberrant activation of nuclear factor-κB, transformed phenotype, and survival of breast cancer cells. Cancer Res 2002;62:6770-6778 (Pubitemid 35364150)
20. Wang D, Westerheide SD, Hanson JL, Baldwin AS, Jr. Tumor necrosis factor α-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem 2000;275:32592-32597
21. Lee TL, Yang XP, Yan B, et al. A novel nuclear factor-κB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res 2007; 13:5680-5691 (Pubitemid 47591640)
22. Friedman J, Nottingham L, Duggal P, et al. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer. Clin Cancer Res 2007;13:6568-6578 (Pubitemid 350206790)
23. Keller DM, Zeng X, Wang Y, et al. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol Cell 2001;7:283-292 (Pubitemid 32206496)
24. Li Y, Keller DM, Scott JD, Lu H. CK2 phosphorylates SSRP1 and inhibits its DNA-binding activity. J Biol Chem 2005;280:11869-11875 (Pubitemid 40418501)
25. Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K. Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol Cancer Res 2004;2:712-721
26. Unger GM, Davis AT, Slaton JW, Ahmed K. Protein kinase CK2 as regulator of cell survival: implications for cancer therapy. Curr Cancer Drug Targets 2004;4:77-84. (Pubitemid 38332566)
27. Ahmad KA, Wang G, Slaton J, Unger G, Ahmed K. Targeting CK2 for cancer therapy. Anticancer Drugs 2005;16:1037-1043
28. Wang G, Unger G, Ahmad KA, Slaton JW, Ahmed K. Downregulation of CK2 induces apoptosis in cancer cells-a potential approach to cancer therapy. Mol Cell Biochem 2005;274:77-84. (Pubitemid 41001503)
29. Fukuhara Y, Takeshima T, Kashiwaya Y, Shimoda K, Ishitani R, Nakashima K. GAPDH knockdown rescues mesencephalic dopaminergic neurons from MPP+-induced apoptosis. Neuroreport 2001; 12:2049-2052 (Pubitemid 32553729)
30. Unger GM. Metal ion-treated biocompatible polymers useful for nanoparticles. PCT/US08/67158. June 14, 2007.
31. Kren BT, Unger GM, Sjeklocha L, et al. Nanocapsule-delivered sleeping beauty mediates therapeutic factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest 2009;119:2086-2099
32. Chen Z, Ricker JL, Malhotra PS, et al. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-κB and activator protein-1 related mechanisms. Mol Cancer Ther 2008;7:1949-1960
33. Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005; 11:28-40. (Pubitemid 40075775)
34. Chen Z, Malhotra PS, Thomas GR, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999;5:1369-1379 (Pubitemid 29282941)
35. Lee TL, Yeh J, Friedman J, et al. A signal network involving coactivated NF-κB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer 2008;122:1987-1998 (Pubitemid 351441187)
36. Deyoung MP, Ellisen LW. p63 and p73 in human cancer: defining the network. Oncogene 2007;26:5169-5183
37. Pena JC, Thompson CB, Recant W, Vokes EE, Rudin CM. Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer 1999;85:164-170 (Pubitemid 29031371)
38. Van Waes C, Kozarsky KF, Warren AB, et al. The A9 antigen associated with aggressive human squamous carcinoma is structurally and functionally similar to the newly defined integrin α6β4. Cancer Res 1991;51:2395-2402
39. Van Waes C. Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. Head Neck 1995;17: 140-147
40. Duncan JS, Litchfield DW. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 2008;1784:33-47.
41. St-Denis NA, Litchfield DW. Protein kinase CK2 in health and disease: from birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival. Cell Mol Life Sci 2009;66: 1817-1829
42. Yde CW, Olsen BB, Meek D, Watanabe N, Guerra B. The regulatory β-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis. Oncogene 2008;27:4986-4997
43. Carroll DK, Carroll JS, Leong CO, et al. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol 2006;8: 551-561 (Pubitemid 43827347)
44. Saha S, Bardelli A, Buckhaults P, et al. A phosphatase associated with metastasis of colorectal cancer. Science 2001;294:1343-1346 (Pubitemid 33063101)
45. Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD, Seldin DC. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 2001;20:3247-3257 (Pubitemid 32553677)
46. Seldin DC, Leder P. Casein kinase II α transgene-induced murine lymphoma: relation to theileriosis in cattle. Science 1995;267:894-897
47. Landesman-Bollag E, Channavajhala PL, Cardiff RD, Seldin DC. p53 deficiency and misexpression of protein kinase CK2α collaborate in the development of thymic lymphomas in mice. Oncogene 1998;16: 2965-2974 (Pubitemid 28297717)
48. Channavajhala P, Seldin DC. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene 2002;21:5280-5288 (Pubitemid 34948139)
49. Orlandini M, Semplici F, Ferruzzi R, Meggio F, Pinna LA, Oliviero S. Protein kinase CK2α' is induced by serum as a delayed early gene and cooperates with Ha-ras in fibroblast transformation. J Biol Chem 1998;273:21291-21297 (Pubitemid 28385422)
50. Belguise K, Guo S, Yang S, et al. Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype. Cancer Res 2007;67: 11742-11750